Identification and validation of novel prognostic biomarkers and therapeutic targets for non-small cell lung cancer

Background: Despite the significant survival benefits of anti-PD-1/PD-L1 immunotherapy, non-small cell lung cancer (NSCLC) remains one of the most common tumors and major causes of cancer-related deaths worldwide. Thus, there is an urgent need to identify new therapeutic targets for this refractory disease. Methods: In this study, microarray datasets GSE27262, GSE75037, GSE102287, and GSE21933 were integrated by Venn diagram. We performed functional clustering and pathway enrichment analyses using R. Through the STRING database and Cytoscape, we conducted protein-protein interaction (PPI) network analysis and identified the key genes, which were verified by the GEPIA2 and UALCAN portal. Validation of actin-binding protein anillin (ANLN) was performed by quantitative real-time polymerase chain reaction and Western blotting. Additionally, Kaplan-Meier methods were used to compute the survival analyses. Results: In total, 126 differentially expressed genes were identified, which were enriched in mitotic nuclear division, mitotic cell cycle G2/M transition, vasculogenesis, spindle, and peroxisome proliferator-activated receptor signaling pathway. 12 central node genes were identified in the PPI network complex. The survival analysis revealed that high transcriptional levels were associated with inferior survival in NSCLC patients. The clinical implication of ANLN was further explored; its protein expression showed a gradually increasing trend from grade I to III. Conclusion: These Key genes may be involved in the carcinogenesis and progression of NSCLC, which may serve as useful targets for NSCLC diagnosis and treatment.

[1]  Feng Jiang,et al.  Methylation Pattern Mediated by m6A Regulator and Tumor Microenvironment Invasion in Lung Adenocarcinoma , 2022, Oxidative medicine and cellular longevity.

[2]  Feng Jiang,et al.  Computational detection of a genome instability‐derived lncRNA signature for predicting the clinical outcome of lung adenocarcinoma , 2021, Cancer medicine.

[3]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[4]  D. Skoufias,et al.  Eg5 Targeting Agents : From new anti-mitotic based inhibitor discovery to cancer therapy and resistance. , 2020, Biochemical pharmacology.

[5]  M. Banerjee,et al.  Centrosomal protein 55: A new paradigm in tumorigenesis. , 2020, European journal of cell biology.

[6]  Hui Wang,et al.  ASPM is a predictor of overall survival and has therapeutic potential in endometrial cancer. , 2020, American journal of translational research.

[7]  A. Hemida,et al.  Evaluation of ASPM and TEF Gene Expressions as Potential Biomarkers for Bladder Cancer , 2020, Biochemical Genetics.

[8]  P. Bie,et al.  ANLN-induced EZH2 upregulation promotes pancreatic cancer progression by mediating miR-218-5p/LASP1 signaling axis , 2019, Journal of experimental & clinical cancer research : CR.

[9]  David C. Smith,et al.  Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab , 2019, JAMA oncology.

[10]  Hong Zheng,et al.  Overexpression of ANLN in lung adenocarcinoma is associated with metastasis , 2019, Thoracic cancer.

[11]  K. Khanna,et al.  Mitotic slippage: an old tale with a new twist , 2019, Cell cycle.

[12]  Damian Szklarczyk,et al.  STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets , 2018, Nucleic Acids Res..

[13]  A. Weeraratna,et al.  Polyunsaturated Fatty Acids from Astrocytes Activate PPAR Gamma Signaling in Cancer Cells to Promote Brain Metastasis. , 2019, Cancer discovery.

[14]  Rong Li,et al.  Cyclin B2 Overexpression in Human Hepatocellular Carcinoma is Associated with Poor Prognosis. , 2019, Archives of medical research.

[15]  A. Das,et al.  Grade-specific diagnostic and prognostic biomarkers in breast cancer. , 2019, Genomics.

[16]  Kelvin K. Tsai,et al.  ASPM promotes prostate cancer stemness and progression by augmenting Wnt−Dvl-3−β-catenin signaling , 2018, Oncogene.

[17]  Hui Zhang,et al.  Effect of CCNB1 silencing on cell cycle, senescence, and apoptosis through the p53 signaling pathway in pancreatic cancer , 2018, Journal of cellular physiology.

[18]  D. Ray,et al.  Molecular Actions of PPARα in Lipid Metabolism and Inflammation. , 2018, Endocrine reviews.

[19]  F. B. Engel,et al.  PPARβ/δ: Linking Metabolism to Regeneration , 2018, International journal of molecular sciences.

[20]  W. Zhou,et al.  Prognostic significance of ANLN in lung adenocarcinoma. , 2018, Oncology letters.

[21]  C. Maxwell,et al.  The nonmotor adaptor HMMR dampens Eg5-mediated forces to preserve the kinetics and integrity of chromosome segregation , 2018, Molecular biology of the cell.

[22]  Roy S. Herbst,et al.  The biology and management of non-small cell lung cancer , 2018, Nature.

[23]  Chad J. Creighton,et al.  UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses , 2017, Neoplasia.

[24]  Walter J Curran,et al.  Lung cancer: current therapies and new targeted treatments , 2017, The Lancet.

[25]  The Gene Ontology Consortium.  Expansion of the Gene Ontology knowledgebase and resources , 2016, Nucleic Acids Res..

[26]  B. Taylor,et al.  Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. , 2017, Cancer discovery.

[27]  F. Pontén,et al.  ANLN is a prognostic biomarker independent of Ki-67 and essential for cell cycle progression in primary breast cancer , 2016, BMC Cancer.

[28]  Jie Wu,et al.  Overexpression of major CDKN3 transcripts is associated with poor survival in lung adenocarcinoma , 2015, British Journal of Cancer.

[29]  L. Borsu,et al.  Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain. , 2015, JAMA oncology.

[30]  Xuekun Song,et al.  CCNB2 overexpression is a poor prognostic biomarker in Chinese NSCLC patients. , 2015, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[31]  M. Malumbres.  Cyclin-dependent kinases , 2014, Genome Biology.

[32]  X. Liang,et al.  Chk1-induced CCNB1 overexpression promotes cell proliferation and tumor growth in human colorectal cancer , 2014, Cancer biology & therapy.

[33]  I. Nakano,et al.  Maternal Embryonic Leucine Zipper Kinase: Key Kinase for Stem Cell Phenotype in Glioma and Other Cancers , 2014, Molecular Cancer Therapeutics.

[34]  A. Shaw,et al.  Novel targets in non-small cell lung cancer: ROS1 and RET fusions. , 2013, The oncologist.

[35]  P. Comoglio,et al.  Oncogenes in non-small-cell lung cancer: emerging connections and novel therapeutic dynamics. , 2013, The Lancet. Respiratory medicine.

[36]  Ana Maria Huaita Alfaro,et al.  Mitosis Is a Source of Potential Markers for Screening and Survival and Therapeutic Targets in Cervical Cancer , 2013, PloS one.

[37]  Sean R. Davis,et al.  NCBI GEO: archive for functional genomics data sets—update , 2012, Nucleic Acids Res..

[38]  M. Ladanyi,et al.  Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations , 2012, Clinical Cancer Research.

[39]  T. Blundell,et al.  BUB1 and BUBR1: multifaceted kinases of the cell cycle , 2011, Trends in biochemical sciences.

[40]  K. Hirata,et al.  The feasibility of Cep55/c10orf3 derived peptide vaccine therapy for colorectal carcinoma. , 2011, Experimental and molecular pathology.

[41]  A. Maddox,et al.  Anillin , 2010, Current Biology.

[42]  Thierry Moreau,et al.  Identifying common prognostic factors in genomic cancer studies: A novel index for censored outcomes , 2010, BMC Bioinformatics.

[43]  E. Chmielik,et al.  NBL1 and anillin (ANLN) genes over-expression in pancreatic carcinoma. , 2009, Folia histochemica et cytobiologica.

[44]  A. Sihoe,et al.  The EML4‐ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type EGFR and KRAS , 2009, Cancer.

[45]  Soon-Cheol Ahn,et al.  Molecular mechanism of diallyl disulfide in cell cycle arrest and apoptosis in HCT‐116 colon cancer cells , 2009, Journal of biochemical and molecular toxicology.

[46]  Phang-lang Chen,et al.  A novel role of the chromokinesin Kif4A in DNA damage response , 2008, Cell cycle.

[47]  K. Gunsalus,et al.  Network modeling links breast cancer susceptibility and centrosome dysfunction. , 2007, Nature genetics.

[48]  Xiuli Jiang,et al.  Aberrant splicing of cyclin-dependent kinase-associated protein phosphatase KAP increases proliferation and migration in glioblastoma. , 2007, Cancer research.

[49]  M. Kallio,et al.  Cenp-F (mitosin) is more than a mitotic marker , 2006, Chromosoma.

[50]  Simon S McDade,et al.  The Septin-Binding Protein Anillin Is Overexpressed in Diverse Human Tumors , 2005, Clinical Cancer Research.

[51]  D. Mount,et al.  Using bioinformatics and genome analysis for new therapeutic interventions , 2005, Molecular Cancer Therapeutics.

[52]  P. Dall,et al.  Expression of the hyaluronan receptor RHAMM in endometrial carcinomas suggests a role in tumour progression and metastasis , 2003, Journal of Cancer Research and Clinical Oncology.